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INTRODUCTION
Asymptomatic prostatic inflammation is of considerable importance to urological research due to its association with two of the most common health concerns in urology: prostate cancer and benign prostatic hyperplasia (BPH). Inflammation in the human prostate is extremely common and is associated with dysplastic changes including focal disruption of the epithelium, polymorphisms of epithelial cell nuclei, and increased epithelial proliferation (Cotran et al, 1999; DeMarzo et al, 2003; McNeal 1968) . Inflammation is manifested by leukocytic infiltration and the release of pro-inflammatory cytokines, chemokines, prostanoids, and growth factors. The origins of inflammation in the prostate remain a subject of debate and are likely multi-factorial.
Infection from culturable and non-culturable organisms causes inflammation in acute and chronic bacterial prostatitis, but these conditions are relatively uncommon (Krieger and Riley, JPET #218693 symptom profile known as lower urinary tract symptoms (LUTS), the disease clearly also includes induced proliferation of both benign epithelial and stromal compartments (Roehrborn, 2008) . Recent reports describe a clear association of BPH with histologically evident inflammation, with the overall prevalence of inflammation in BPH specimens ranging from 75 to 100%. A recent prospective study of autopsy specimens found chronic inflammation in 75% of prostates obtained from 93 men with histological evidence of BPH compared to 50% of prostates not affected by BPH (Delongchamps et al, 2008) . A second study found substantial prostatic inflammation in 100% of 80 men undergoing prostatectomy for treatment of BPH (Nickel et al, 1999) . Further, prostate biopsies of 8224 men enrolled in the REDUCE trial revealed inflammation in 78% of specimens, and survey studies have characterized BPH-associated inflammation as having an abundance of T-cells, high expression of a variety of inflammatory cytokines, including IL-1, IL-6, and IL-8, which are well-characterized inducers of prostatic proliferation and growth (Steiner et al, 2003; Nickel et al, 2007b) . Perhaps most importantly, the Medical Therapy of Prostate Symptoms (MTOPS) study found that the most tightly-correlated histological finding to prostate symptomology and growth is the presence of prostatic inflammation (Nickel et al, 2008) . These reports clearly suggest a significant role for inflammation in BPH and define the need for a mechanistic understanding. JPET #218693 6 et al, 2001; McLaren et al, 2011) . These reports suggested to us that IGF signaling may serve as a bridge between inflammatory signaling and the induction of cell proliferation. Here, we show that inflammation of the prostate causes rapid and substantial induction of IGF signaling in the mouse prostate, that the proliferative response of the tissue to inflammation is dependent upon IGF signaling, and that human prostatic hyperplasia is associated with IGF pathway activation that is specifically localized to foci of inflammation. This demonstrates that the mechanism of inflammation-induced epithelial proliferation and prostatic hyperplasia involves the induction of developmental growth factors providing a mechanistic basis for the management of proliferative prostatic diseases such as BPH.
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MATERIALS AND METHODS
In vivo induction of inflammation, proliferation, and assessment of reactive hyperplasia
All animal experiments were conducted under the approval and supervision of the Indiana University School of Medicine Animal Care and Use Committee, and in accordance of NIH guidelines for animal research. E. coli strain 1677 (2 x 10 6 /ml, 100 μ l per mouse) was instilled through catheters into the urinary tract of C57BK WT and IL-1R1 (-/-) mice (The Jackson Laboratory, Bar Harbor, ME; verified by genotyping) at 8 weeks of age as previously described (Jerde et al, 2009 ). Mice were inoculated with 100 mg of BrdU (Roche) 2 hours prior to sacrifice, and groups were sacrificed daily 1-7 days after induction. PBS-instilled animals were used as naïve controls. Prostate tissues were either paraffin-embedded for histological and immunohistochemical analysis, snap-frozen for molecular analysis, or incubated in Krebs buffer for release experiments as described below.
The severity of the inflammatory response as noted in Fig. 5 was graded as previously described (Boehm, Colopy, et al, 2012) in three random 20x fields of H&E sections according to four criteria: inflammatory infiltrate, tissue damage, hyperplastic response, and hemorrhage.
Leukocytes were counted and each field given a score as follows: 0, no leukocytes; 1 (mild) less than 10 leukocytes; 2 (moderate) 10-30 leukocytes; or 3 (severe) greater than 30 leukocytes. The focality of tissue damage based on the integrity of the epithelium and the presence of visibly damaged cells (or pyknotic nuclei was scored as: 0, full epithelial integrity and no damaged cells; 1 (mild) sloughed epithelium in less than 25% of a ductal cross section and/or 1-20 damaged A subset of mice received the IGF receptor antagonist picropodophyllin (PPP) (for synthesis and structure, see Berkowitz et al, 2000) concurrent with inflammation to generate the data displayed in Figures 5 and 6 . This was performed with a protocol adapted from previous reports. (Razuvaev et al, 2008) In this experiment, C57 wildtype or IL-1R1 (-/-) mice were injected twice daily (every 12 hours, plus or minus 30 minutes) with PPP (10 mg/kg/i.p.) in a total volume of 50 μl 75% corn oil, 25% DMSO prior to and during the inflammatory period. The first two treatments for each animal were 24 and 12 hours prior to induction of inflammation, and the This article has not been copyedited and formatted. The final version may differ from this version. 
Protein quantification by immunoblotting
Total protein quantification as shown in Fig. 2A and NaCl, 10 mM tris, 1 mM EDTA, 1 mM benzenesulfonyl fluoride, and 10 μ g/ml each of aprotinin, bestatin, L-leucine, and pepstatin A). Triton X-100 was added to a concentration of 1%, and the homogenate was incubated on ice for 60 min, followed by centrifugation for 20 min at 14,100g
at 4°C. The supernatant was collected and total protein concentration was determined by BCA 
Protein localization by immunofluorescence:
Inflamed and naïve prostate specimens were fixed in 10% phosphate-buffered formalin overnight, processed and embedded in paraffin, and cut into 5-μm sections with a microtome. Tissues were 
Statistical Analysis
Two-way analysis of variance (ANOVA) was performed to determine the significance of treatment group and day of sacrifice (SAS 9. 
RESULTS
Inflammation induces a pro-proliferative shift in the expression of IGF pathway components in the prostate
We induced inflammation in mouse prostates using our established model of uropathogenic E. coli 1677 instilled via catheter into the urinary tract (Boehm and Colopy et al, 2012) . This model induces a reproducible inflammatory response characterized by tissue damage, The IGF signaling pathway is activated during prostatic inflammation.
Upon activation by IGF ligand, the dimerized IGF receptor (IGFR1) is phosphorylated at tyrosine 1161 in its intracellular SH1 domain (Vincent and Feldman, 2002) . reports (Delongchamps et al, 2008; Nickel et al, 2008; Bostanci et al, 2013) , BPH specimens exhibited significantly more areas of inflammation than control prostates. All 6 TURP specimens analyzed exhibited widespread and severe inflammation while control prostates exhibited focal and moderate to slight inflammation. Regardless, the presence of inflammation juxtaposed to prostatic inflammation was directly correlated to IGFR1 activation, often resulting in histological reactive hyperplasia of the epithelium, [ Fig. 3D ] and the difference in IGF activation between BPH and control was a direct function of inflammatory intensity.
Genetic IL-1R knockdown attenuates inflammation-induced IGF signaling.
Inflammation-induced IGF-1 activity is reduced in IL-1R1 (-/-) mice. We infected IL-1R1 found that activation of the IGF-1 receptor was also attenuated by 60% in immunoblots, and that IGF-R1 phosphorylation was evident in a significantly reduced number of cells by immunofluorescence. [Fig. 4 ] Quantified data from 4 inflamed dorsal-lateral prostates show that IGF-1R is active in 24% of cells in the wild-type inflamed prostates and only 3.2% of IL-1R1 (-/-) prostates. We had previously published that IL-1 induced IGF expression was dependent upon STAT3 signaling in developing prostates, and that STAT3 activation occurs in the stroma of 
DISCUSSION
The IGF pathway is regulated in a pro-proliferative direction during prostatic inflammation, resulting in downstream pathway activation and epithelial proliferation and reactive hyperplasia. Specifically, the IGF-1 pathway ligand exhibits mRNA induction that is evident the second day after induction of inflammation, and maximizes at three days post induction. Peptide production of IGF-1 ligand corresponds to this induction. IGF-1 peptide secretion appears to follow a regulated pattern in which increased IGF-1 is actively released, but retention of peptide occurs upon the resolution phase of the inflammatory process at day 5.
Conversely, IGF-2 expression does not appear to be induced in our model of prostatic inflammation, but the regulated release of the peptide does appear to increase, suggesting that peptide release is an active point of IGF regulation in response to inflammation. Concentrations of both IGF peptides and IGF signaling pathway activation return to normal after 7 days of inflammation in this model.
Our data further indicate that pharmacological IGF pathway inhibition attenuates inflammatory reactive hyperplasia in the mouse prostate. It is important to note that IGF and IGF receptor null mice are available but would not be applicable to use in the prostate for these studies due to the lack of prostatic tissue, given that IGF is indispensable for prostate development (Ruan et al, 1999) . Previous reports indicate that the pharmacological inhibitor picropodophyllin (PPP) is effective in vivo at attenuating intimal hyperplasia (Cohen et al, 1991) .
We adapted this protocol to be applicable toward inflammation-induced hyperplasia of the prostate because the higher DMSO volumes used in the previous study produced unacceptable other cytokines can be induced by IL-1 (Garlanda et al, 2013) . Therefore, future work in this area would include further investigation of the role of inflammatory mediators in growth factorinduced hyperplasia. Therefore in summary [ Supplementary Figure 1] , our data propose the model that IL-1 produced during prostatic inflammation signals to the IL-1R1 receptor on responsive stromal cells, resulting in IGF production and proliferative signaling in the prostatic epithelium, resulting in hyperplasia. This model recapitulates the events that occur during prostate development.
While inflammation in the mouse model is transient, and therefore IGF-1 induction is transient, the chronic and recurrent inflammation observed in human BPH specimens results in sustained IGF pathway activation. Activation of the IGF signaling pathway occurs in the epithelium of human BPH specimens specifically juxtaposed to areas of inflammation. An important observation from our data is that inflammation when present in non-diseased prostates also induces IGF signaling concurrent with proliferation. The primary difference between BPH specimens and non-diseased specimens involving IGF signaling does not seem to be how the prostatic microenvironment responds to inflammation, but rather is related to how much inflammation occurs in each situation. While non-diseased specimens exhibit inflammation rarely and in limited focal pattern, inflammation in highly symptomatic TURP-removed BPH specimens was severe and widespread. As reported by Nickle and others (Nickel et al, 2008; Delongchamps et al, 2008; Bostanci et al, 2013) , our observations are that inflammation is a uniform pathology of BPH specimens but is much less prevalent in normal conditions. This severe and widespread inflammation results in activated IGF signaling and the promotion of hyperplasia. Therefore, these data add to the growing evidence suggesting a proliferative role for inflammation in the progression of BPH.
This article has not been copyedited and formatted. The final version may differ from this version. The critical role for IGF signaling in prostatic growth is well-established, however a pathological role for IGF in BPH has been difficult to elucidate. IGF promotes epithelial growth in tissue culture studies and in vivo (Cohen et al, 1991; Plymate et al, 1996) . IGF overexpression exhibits a potent growth-promoting effect for IGF in the prostate and results in hyperplasia (Kaplan-Lefko et al, 2008; DiGiovanni et al, 2000) . Further, Ruan and Kleinberg demonstrated that IGF-I is required for prostate development (Ruan et al, 1999) . However, conflicting reports exist regarding in vivo effects of IGF in humans. Circulating IGF serum concentrations have been analyzed by several groups with no consensus casting doubt upon a critical role for IGF in BPH pathology (Stattin et al, 2001; Latif et al, 2002; Khosravi et al, 2001) . These data analyzing circulating serum IGF concentrations ignore the role of locally-induced IGF on growth, and a careful analysis of TURP specimens removed for BPH symptoms was clearly warranted. In developing prostatic growth, locally-expressed IGF is indispensable for prostate growth (Ruan et al, 1999) , and IGF is highly induced by local inflammatory mediators during development (Jerde and Bushman, 2009) . Given the intensity of inflammation in BPH in previous reports and our own analysis, a recapitulation of this IL-1-IGF signaling loop seemed plausible. The present data therefore sheds significant new light by identifying that locally-produced IGF serves as a critical intermediary between inflammation and proliferation in the prostate.
While the present study is primarily focused on a role for inflammation-induced proliferation in a benign setting, the relevance of these results may extend into malignant prostate pathology as well. A rapidly accumulating body of evidence links the presence and activity of inflammation to the development of cancer in the prostate (Rokman et al, 2002 (Rokman et al, 2002; Xu et al, 2002) . Further, histopathology studies of human prostatectomy specimens identified lesions characterized by proliferating epithelial cells and activated inflammatory cells (proliferative inflammatory atrophy, PIA) in juxtaposition to areas of neoplasia (De Marzo et al, 1999; Nelson et al, 2004) . The sustained cell proliferation in an environment rich in inflammatory cells, growth factors, activated stroma, and DNA-damagepromoting agents, could potentiate and/or promote neoplasia (De Marzo et al, 1999) . Cytokines are induced locally in prostate cancer microenvironment, and are known to induce proliferation of prostate cancer cells in vitro and in vivo (Culig, 2011; Karkera et al, 2011) . In addition, proliferative inflammatory atrophy (PIA), a histological lesion characterized by proliferating epithelial cells and activated inflammatory cells, is often found in association with prostatic intra-epithelial neoplasia (PIN) and prostate cancer and has been postulated to represent a premalignant lesion (Nelson et al, 2004) . Loss of glutathione-s-transferase-π1 (GSTP1) gene product is detected in a high proportion of PIN and cancer specimens and is considered a critical event that renders prostatic epithelial cells more vulnerable to genomic damage mediated by reactive oxygen and nitrogen species (Nelson et al, 2001 ). These findings have prompted the hypothesis that chronic inflammation is involved in the genesis and/or progression of prostate cancer, and an activation of growth factor signaling may be one mechanism for how inflammation orchestrates a pro-proliferative microenvironment.
Taken in total, these cell culture, animal, and human data demonstrate a significant role 
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